Here's why the Noxopharm (ASX:NOX) share price is surging 6% higher

Here's why the Noxopharm Ltd (ASX:NOX) share price is charging higher on Tuesday morning following the release of a positive announcement…

| More on:
Five stacked building blocks with green arrows, indicating rising inflation or share prices

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Noxopharm Ltd (ASX: NOX) share price has started the week on a positive note.

At the time of writing, the clinical-stage drug development company's shares are up 6% to 67 cents.

Why is the Noxopharm share price charging higher?

Investors have been buying Noxopharm's shares after it provided an update on its Veyonda product.

According to the release, the company has lodged an international patent application aimed at protecting the use of Veyonda in blocking the development of septic shock associated with infections such as COVID-19 and influenza viruses.

Veyonda is being developed as an anti-cancer drug that enhances the effectiveness of standard anticancer treatments.

The release notes that one of its anti-cancer actions is the blocking of a signalling pathway called STING that serves as trigger for an immune response and repair of damaged tissue. In some individuals, the STING response is inappropriately excessive, pushing the individual over into septic shock. Veyonda appears to be the first drug that blocks STING in the clinic.

With an estimated one person dying globally every 3 seconds from cancer and one every 3 seconds from septic shock, management notes that the commercial opportunity for Veyonda has just doubled. It feels this underlines the commercial importance of the recent patent lodgement.

What about COVID-19?

The company advised that "long COVID" symptoms, such as long-lasting fatigue, breathing problems, headaches, along with severe organ damage and death, are all outcomes associated with septic shock.

Septic shock currently is managed with supportive treatments including drugs and fluids to restore blood pressure, anti-inflammatories such as dexamethasone, and antibiotics/antivirals. However, Noxopharm notes that the key need, that of providing a reduction in cytokine levels in a safe and comprehensive manner, remains largely unmet.

As a result, it sees a significant opportunity for the Veyonda product in this market.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Gainers

Happy teen friends jumping in front of a wall.
Share Gainers

Guess which 4 ASX 200 shares are rocking new 52-week highs today!

Investors just sent these four ASX 200 shares to one-year-plus highs.

Read more »

Two happy excited friends in euphoria mood after winning in a bet with a smartphone in hand.
Share Gainers

Why Evolution Mining, Orthocell, Platinum, and Turaco shares are charging higher

These shares are having a better day that most on Thursday.

Read more »

A man looking at his laptop and thinking.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a disappointing hump day session for the ASX today.

Read more »

The silhouettes of ten people holding hands with their arms raised against the sky, as the sun rises or sets in the background.
Share Gainers

Here are the top 10 ASX 200 shares today

The ASX managed to bank a small rise this Tuesday.

Read more »

Sport trainer talking to little girl who is climbing wooden ladder in gym.
Share Gainers

Why Vault Minerals, Droneshield, Westgold Resources shares are climbing higher today

These shares are gaining on Tuesday, but why?

Read more »

A young woman smiles as she rides a zip line high above the trees.
Financial Shares

5 best ASX 200 financial shares of FY25 (CBA didn't make the cut!)

These stocks were well and truly 'in the black' for share price growth last financial year.

Read more »

Excited group of friends sitting on sofa watching sports on TV and celebrating.
Share Gainers

Why Amaero, Black Cat, Domino's, and Ramelius shares are racing higher today

These shares are having a good session on Tuesday. But why?

Read more »

Ten happy friends leaping in the air outdoors.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a rough start to the trading week for investors this Monday.

Read more »